First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(3 sites)

France

Institut de Radiothérapie du Sud de l'Oise, Creil, Hauts-de-France

Centre Sainte-Catherine, Avignon, Provence-Alpes-Côte d'Azur Region

Gustave Roussy, Villejuif, Île-de-France Region